Unitra 250 mg (Tranexamic Acid)

Adult dosage

(Capsule form) The usual adult dose is 750–2000 mg of tranexamic acid daily, divided into 3–4 oral doses. Dosage may be adjusted according to age and symptoms. (Injection form) The usual adult dose is 250–500 mg of tranexamic acid daily, divided into 1–2 intravenous or intramuscular injections. For bleeding during or after surgery, a single dose of 500–1000 mg can be administered intravenously or 500–2500 mg via drip intravenous injection.

This medication is an ampoule injection, and when opening the container, glass fragments may enter, so extra caution should be taken when cutting the container, especially for children or the elderly, to prevent the glass from getting mixed in. This medication should not be used in patients receiving thrombin or in patients with a history of thromboembolism. Additionally, individuals with allergic reactions to this drug or its components should not take it, and it must not be used via epidural or intrathecal routes as it is dangerous. Caution should be taken when using this medication in patients with thrombosis or a high risk of thrombosis, patients on bed rest post-surgery, patients with impaired renal function, and those with specific bleeding disorders. This medication may occasionally cause shock, allergic reactions, skin rashes, itching, temporary visual disturbances, gastrointestinal symptoms (nausea, vomiting, diarrhea), dizziness, and headache, so if any unusual symptoms occur, administration should be stopped immediately, and appropriate treatment sought. Particular care is needed as convulsions may occur in patients who receive this medication during cardiovascular surgery. This medication can promote thrombus formation; thus, when used in conjunction with other drugs that affect blood coagulation, the risk of thrombosis may increase, so it should be used with caution as directed by a professional. In pregnant women, it should be administered with caution as it can cross the placenta, and during breastfeeding, small amounts may be secreted in breast milk with little expected effect on infants. Elderly patients may have decreased bodily functions, so doses should be adjusted and used with caution. In cases of overdose, symptoms such as nausea, vomiting, and hypotension may occur, so if overdose is suspected, adequate hydration and immediate medical help should be sought. Administer slowly via intravenous injection; injecting too quickly may cause nausea, chest discomfort, palpitations, and dizziness. Finally, when using this medication with certain other injectable agents or hemostatic agents, drug interactions may elevate thrombus formation risks, so it is essential to consult with a specialist.

Serious side effects

• Shock
• thromboembolism
• convulsions
• seizures

Mild side effects

• Itching
• rash
• flushing
• temporary color perception abnormalities
• nausea
• vomiting
• diarrhea
• drowsiness
• headache
• chest discomfort

This medication should be stored in a sealed container to prevent air and moisture from entering, and it is best to maintain a storage temperature between 1°C and 30°C room temperature. Storing it this way will help maintain the drug's effectiveness for a longer period.

Appearance

For domestic use and export 1: colorless ampoule containing a colorless, transparent liquid Export 2: ampoule containing a clear, colorless liquid

Package unit

5 mL × 10 ampoules